Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

view original post



Every so often, there comes a time when dividend investors can catch a once-in-a-lifetime sale on a high-quality company. I believe that Bristol Myers Squibb (NYSE:BMY) is this next opportunity, as the price has fallen nearly 40% over

Product Use Approx. Annual Revenue Patent Expiry
Eliquis Anticoagulant $12B 2026
Opdivo Cancer (immunotherapy) $9B 2026
Revlimid Blood Cancer $6.6B Started In 2022
Pomalyst Blood Cancer $3.5B 2026
Orencia Rheumatoid $3.2B Started In 2021
Yervoy Cancer $2.3B 2028
Sprycel Leukemia $1.5B 2026